Xu, Jing
Zhang, Wen
Tong, Jinlian
Liu, Caixia
Zhang, Qiaohui
Cao, Liren
Yu, Jiangyong
Zhou, Aiping
Ma, Jie
Funding for this research was provided by:
National High Level Hospital Clinical Research Funding (No. BJ-2022-118)
National Major Scientific and Technological Special Project for “Significant New Drugs Development” (2016ZX09101094)
Article History
Received: 26 October 2023
Accepted: 17 March 2024
First Online: 20 April 2024
Declarations
:
: All the authors declare no potential conflicts of interest.
: The trial was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR1900021334). The study protocol was approved by Cancer Hospital of Chinese Academy of Medical Sciences Ethics Committee. This study was conducted in accordance with the Declaration of Helsinki provisions. All patients provided written informed consent.